Withings announces hands-free connected in-home urine lab
January 6, 2023Medical Communications
Connected health firm Withings has unveiled its new in-home biomarker analysis platform U-Scan. It is hoped the device will utilise …
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
January 5, 2023Medical Communications
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for …
Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer
January 5, 2023Business Services
BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced …
Lidia Oostvogels
January 5, 2023Business Services
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
January 5, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that …
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
January 5, 2023Business Services
Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
January 5, 2023Business Services
Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
FDA accepts application for nirsevimab as first protective option for RSV in infants
January 5, 2023Medical Communications
The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease …
Island Pharmaceuticals to begin phase 2 trial for dengue prevention and treatment drug
January 5, 2023Research and Development
It is possible that Island Pharmaceuticals could begin its phase 2a PEACH clinical trial as soon as January 2023. The …
Belharra Therapeutics and Genentech join forces for small molecule medicine development
January 5, 2023Research and Development
US-based biotech companies Belharra Therapeutics and Genentech have announced a multi-year partnership to lead the discovery and development of small …
Biogen and Alcyone Therapeutics enter partnership to develop ThecaFlex DRx system for ASO therapies
January 5, 2023Research and Development
US-based Biogen and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System. …
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
January 4, 2023Business Services
Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
January 4, 2023Business Services
Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …
Dr Samson Fung
January 4, 2023Business Services
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing …
Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
January 4, 2023Business Services
London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …
FDA expands access to abortion pills
January 4, 2023Medical Communications
Following new rules from the FDA under the Biden administration, patients can now obtain the abortion pill mifepristone from retail …
Novartis pays $245m to settle Exforge generic pay-for-delay lawsuit
January 4, 2023Medical Communications
Swiss pharma company Novartis will settle a classic generic pay-for-delay legal battle with direct purchasers, indirect purchasers and retailers regarding …
FDA grants Breakthrough Device Designation for Burning Rock’s multi-cancer detecting test
January 4, 2023Medical Communications
Burning Rock, a Chinese biotech company which focuses on the applications of next-generation sequencing (NGS) technology in the field of …
FDA expected to make decision on controversial Alzheimer’s drug this week
January 4, 2023Medical Communications
The FDA are expected to come to a decision on Eisai and Biogen’s Alzheimer’s drug lecanemab by the end of …
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
January 3, 2023Business Services
Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
